肝吸蟲治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球肝吸蟲治療市值為 6.188 億美元，預計 2025 年至 2034 年的複合年成長率為 4.8%，這得益於肝吸蟲感染患病率的增加和抗寄生蟲藥物配方的進步。肝吸蟲是一種影響人類和動物的寄生蟲疾病，會帶來嚴重的健康風險，包括肝損傷、膽管感染，甚至膽管癌。人們對這些健康併發症的認知不斷提高，刺激了對有效治療方案的需求。製藥公司正在大力投資研發，以推出可提高藥物療效、生物利用度和可及性的創新療法。

這一市場的擴張很大程度上受到人們對早期診斷和治療的日益重視以及驅蟲藥物日益普及的影響。世界各地的衛生組織都在強調預防措施和治療策略以控制感染率，預計這將進一步推動市場需求。藥物配方技術的進步，包括控制藥物釋放機制和提高生物利用度，也促進了市場擴張。此外，遠距醫療和線上醫藥平台的廣泛整合使偏遠和服務欠缺地區更容易獲得肝吸蟲治療，進一步提高了市場滲透率。

市場按製劑類型細分，包括片劑、注射劑和口服混懸液。平板電腦在 2024 年佔據了 41.4% 的市場佔有率，預計到 2034 年將以 4.7% 的複合年成長率成長。其較長的保存期限和最低的儲存要求使其成為首選，尤其是在冷藏條件有限的地區。片劑配方的創新，例如改進的控釋機制，正在提高藥物療效和患者依從性。隨著製藥公司不斷改進口服藥物，預計整個預測期內對藥片的需求將保持強勁。

根據應用，市場分為人類治療和動物治療。 2024 年，人力資本市場創造了 3.694 億美元的收入，預計到 2034 年將達到 5.758 億美元，複合年成長率為 4.6%。人們越來越意識到肝吸蟲感染相關的健康風險，包括肝硬化和膽管癌等嚴重疾病，這推動了對有效治療的需求。獸醫應用在市場擴張中也發揮著至關重要的作用，因為受感染的牲畜是人類的主要傳播源。控制動物感染的努力仍然是全球衛生當局的首要任務，這進一步促進了市場的成長。

2024年美國肝吸蟲治療市值為2.25億美元。驅蟲藥物的進步顯著提高了治療效果，導致公認的療法廣泛採用。美國製藥業持續推動創新，正在進行的研究重點是擴大治療選擇和改進藥物配方。美國肝吸蟲感染發生率不斷上升，部分原因是來自流行地區的移民，這進一步刺激了市場擴張。隨著持續的研發舉措和不斷成長的醫療保健投資，肝吸蟲治療市場預計將在未來幾年實現持續成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 肝吸蟲感染盛行率不斷上升
    • 診斷技術的進步
    • 畜牧業蓬勃發展
    • 有效療法的可用性
  • 產業陷阱與挑戰
    • 來自替代療法的競爭
    • 對常用驅蟲藥的抗藥性
• 成長潛力分析
• 監管格局
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按藥物類型，2021 年至 2034 年

• 主要趨勢
• 三氯苯達唑
• 吡喹酮
• 硫醇
• 阿苯達唑
• 硝唑尼特
• 其他藥物類型

第6章：市場估計與預測：依配方類型，2021 年至 2034 年

• 主要趨勢
• 平板電腦
• 注射
• 口服懸浮液

第7章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 人類
• 動物

第8章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 診所
• 獸醫設施
• 其他最終用途

第9章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• AdvaCare Pharma
• Bayer Healthcare
• GlaxoSmithKline
• Lupin Pharma
• Merck
• Novartis
• Par Pharmaceutical
• Pfizer
• Schering Corporation
• Vetoquinol
• Virbac
• Zoetis

The Global Liver Fluke Treatment Market was valued at USD 618.8 million in 2024 and is projected to register a CAGR of 4.8% from 2025 to 2034, driven by the increasing prevalence of liver fluke infections and advancements in antiparasitic drug formulations. Liver fluke, a parasitic disease affecting both humans and animals, poses severe health risks, including liver damage, bile duct infections, and even bile duct cancer. The rising awareness of these health complications has spurred demand for effective treatment options. Pharmaceutical companies are investing heavily in research and development to introduce innovative therapies that enhance drug efficacy, bioavailability, and accessibility.

The expansion of this market is largely influenced by the growing focus on early diagnosis and treatment, as well as the increasing adoption of anthelmintic medications. Health organizations worldwide are emphasizing preventive measures and treatment strategies to curb infection rates, which is expected to further propel market demand. Technological advancements in pharmaceutical formulations, including controlled drug release mechanisms and improved bioavailability, are also contributing to market expansion. Additionally, the widespread integration of telemedicine and online pharmaceutical platforms is making liver fluke treatment more accessible in remote and underserved areas, further boosting market penetration.

The market is segmented by formulation type, including tablets, injections, and oral suspensions. Tablets held a 41.4% market share in 2024 and are expected to grow at a CAGR of 4.7% through 2034. Their extended shelf life and minimal storage requirements make them the preferred choice, especially in regions with limited access to refrigeration. Innovations in tablet formulations, such as improved controlled-release mechanisms, are enhancing drug efficacy and patient compliance. As pharmaceutical companies continue to refine oral medications, the demand for tablets is expected to remain strong throughout the forecast period.

By application, the market is categorized into human and animal treatment. The human segment generated USD 369.4 million in 2024 and is projected to reach USD 575.8 million by 2034, growing at a CAGR of 4.6%. Rising awareness about the health risks associated with liver fluke infections, including serious conditions such as liver cirrhosis and bile duct cancer, has driven the demand for effective treatments. Veterinary applications also play a crucial role in market expansion, as infected livestock serve as a primary transmission source for humans. Efforts to control infections in animals remain a priority for global health authorities, further contributing to market growth.

The US liver fluke treatment market was valued at USD 225 million in 2024. Advances in anthelmintic medications have significantly improved treatment efficacy, leading to the widespread adoption of recognized therapies. The US pharmaceutical industry continues to drive innovation, with ongoing research focused on expanding treatment options and improving drug formulations. The rising incidence of liver fluke infections in the US, partly attributed to immigration from endemic regions, has further fueled market expansion. With continuous research and development initiatives and growing healthcare investments, the liver fluke treatment market is expected to witness sustained growth in the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of liver fluke infection
    • 3.2.1.2 Advancements in diagnostic techniques
    • 3.2.1.3 Growing livestock industry
    • 3.2.1.4 Availability of effective therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Competition from alternative treatments
    • 3.2.2.2 Resistance to commonly used anthelmintic drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Triclabendazole
• 5.3 Praziquantel
• 5.4 Bithionol
• 5.5 Albendazole
• 5.6 Nitazoxanide
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Injections
• 6.4 Oral suspension

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Humans
• 7.3 Animals

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Veterinary facilities
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AdvaCare Pharma
• 10.2 Bayer Healthcare
• 10.3 GlaxoSmithKline
• 10.4 Lupin Pharma
• 10.5 Merck
• 10.6 Novartis
• 10.7 Par Pharmaceutical
• 10.8 Pfizer
• 10.9 Schering Corporation
• 10.10 Vetoquinol
• 10.11 Virbac
• 10.12 Zoetis